Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO9XTJ)

Drug Name

Quinelorane Drug Info

Synonyms

Quinelorane; Quinelorane [INN:BAN]; Quineloranum [INN-Latin]; UNII-Z0X4VT3Y1Q; Quinelorano [INN-Spanish]; 97466-90-5; Z0X4VT3Y1Q; LY 163502; LY 137157; LY 175877; CHEMBL155731; (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine; (5aR-trans)-5,5a,6,7,8,9,9a,10-Octahydro-6-propylpyrido(2,3-g)quinazolin-2-amine; Pyrido(2,3-g)quinazolin-2-amine, 5,5a,6,7,8,9,9a,10-octahydro-6-propyl-, (5aR-trans)-; DSSTox_RID_81533; DSSTox_CID_26315; DSSTox_GSID_46315; Quineloranum; Quinelorano; CAS-97466-90-5

Indication

Disease Entry	ICD 11	Status	REF
Male sexual disorder	HA02.0	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 57242
ChEBI ID: CHEBI:92230
CAS Number: CAS 97466-90-5
TTD Drug ID: DMO9XTJ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[3]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[4]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[4]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[5]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[6]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[7]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[8]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[9]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[10]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 954).
2	Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies.Pharmacol Biochem Behav.2008 Oct;90(4):686-90.
3	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
6	Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
10	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).